{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:40:09Z","timestamp":1746330009013,"version":"3.40.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017959","name":"Hebei Provincial Health Commission","doi-asserted-by":"crossref","award":["29384726"],"award-info":[{"award-number":["29384726"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Idiopathic membranous nephropathy (IMN) is one of the leading causes of nephrotic syndrome in adults. We performed a protocol for systematic review and meta-analysis to compare the efficacy and safety of cyclophosphamide (CTX) with calcineurin inhibitors (CNIs) in the treatment of IMN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and 3 Chinese databases (WanFang Data, Chongqing VIP and China National Knowledge Infrastructure) were searched from inception through January 2022 to identify randomized controlled trials that compared CTX with CNIs for patients with IMN. Systematic review and meta-analysis of the data will be performed in RevMan software (version 5.3) according to the preferred reporting items of systematic reviews and meta-analysis guidelines. Two authors independently performed the literature searching, data extraction, and quality evaluation. Risk of bias was assessed using the Cochrane Risk of Bias Tool for randomized controlled trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results will be submitted to a peer-reviewed journal once completed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The conclusion of our research will provide evidence to help physicians to decide between CTX and CNIs therapy regimens for IMN patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Open Science Framework registration number:<\/jats:title>\n            <jats:p>10.17605\/OSF.IO\/G584K<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028891","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T13:18:33Z","timestamp":1645795113000},"page":"e28891","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of cyclophosphamide and calcineurin inhibitors for idiopathic membranous nephropathy"],"prefix":"10.1097","volume":"101","author":[{"given":"Kang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-2845","authenticated-orcid":false,"given":"Junjie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17589.1","article-title":"Immunology of membranous nephropathy","volume":"8","author":"Akiyama","year":"2019","journal-title":"F1000Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/postgradmedj-2018-135729","article-title":"Primary membranous nephropathy: comprehensive review and historical perspective","volume":"95","author":"Keri","year":"2019","journal-title":"Postgrad Med J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MNH.0000000000000697","article-title":"Membranous nephropathy: current understanding of various causes in light of new target antigens","volume":"30","author":"Ronco","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1038\/ki.1980.1","article-title":"In situ immune complex formation and glomerular injury","volume":"17","author":"Couser","year":"1980","journal-title":"Kidney Int"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5455\/medarh.2020.74.228-232","article-title":"Idiopathic membranous nephropathy and treatment related complications","volume":"74","author":"Uncanin","year":"2020","journal-title":"Med Arch"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1681\/ASN.2012010058","article-title":"Treatment of idiopathic membranous nephropathy","volume":"23","author":"Waldman","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/imj.14446","article-title":"Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy","volume":"50","author":"Zou","year":"2020","journal-title":"Intern Med J"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/0886022X.2019.1637758","article-title":"Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy","volume":"41","author":"Zou","year":"2019","journal-title":"Ren Fail"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/0886022X.2017.1373130","article-title":"Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety","volume":"39","author":"Yu","year":"2017","journal-title":"Ren Fail"},{"key":"R12-20250504","first-page":"2693","article-title":"Effect of tacrolimus in idiopathic membranous nephropathy: a meta-analysis","volume":"127","author":"Santosh","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e5976","DOI":"10.1590\/1414-431x20175976","article-title":"Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy","volume":"50","author":"Cui","year":"2017","journal-title":"Braz J Med Biol Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am J Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:22:27Z","timestamp":1746328947000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028891"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028891","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"2022-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}